An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 27 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Feb 2013 Actual initiation date changed from Nov 2012 to Jan 2013, as reported by ClinicalTrials.gov.
- 26 Jan 2013 New trial record